Douglas G. Mashek, Salmaan A. Khan, Aishwarya Sathyanarayan, Jonathan M. Ploeger, Mallory P. Franklin – 8 April 2015 – Hepatic steatosis is defined by the accumulation of lipid droplets (LDs). Once thought to be only inert energy storage depots, LDs are increasingly recognized as organelles that have important functions in hepatocytes beyond lipid storage. The lipid and protein composition of LDs is highly dynamic and influences their intrinsic metabolism and signaling properties, which ultimately links them to the changes in hepatic function.

Huey‐Ling Chen, Chien‐Nan Lee, Chin‐Hao Chang, Yen‐Hsuan Ni, Ming‐Kwang Shyu, Shih‐Ming Chen, Jen‐Jan Hu, Hans Hsienhong Lin, Lu‐Lu Zhao, Shu‐Chi Mu, Ming‐Wei Lai, Chyi‐Long Lee, Hsien‐Ming Lin, Ming‐Song Tsai, Jenn‐Jeih Hsu, Ding‐Shinn Chen, K. Arnold Chan, Mei‐Hwei Chang, Taiwan Study Group for the Prevention of Mother‐to‐Infant Transmission of HBV (PreMIT Study) – 7 April 2015 – The efficacy and safety of maternal tenofovir disoproxil fumarate (TDF) in reducing mother‐to‐infant hepatitis B virus (HBV) transmissions is not clearly understood.

Huey‐Ling Chen, Chien‐Nan Lee, Chin‐Hao Chang, Yen‐Hsuan Ni, Ming‐Kwang Shyu, Shih‐Ming Chen, Jen‐Jan Hu, Hans Hsienhong Lin, Lu‐Lu Zhao, Shu‐Chi Mu, Ming‐Wei Lai, Chyi‐Long Lee, Hsien‐Ming Lin, Ming‐Song Tsai, Jenn‐Jeih Hsu, Ding‐Shinn Chen, K. Arnold Chan, Mei‐Hwei Chang, Taiwan Study Group for the Prevention of Mother‐to‐Infant Transmission of HBV (PreMIT Study) – 7 April 2015 – The efficacy and safety of maternal tenofovir disoproxil fumarate (TDF) in reducing mother‐to‐infant hepatitis B virus (HBV) transmissions is not clearly understood.

Stanislas Pol, Mark S. Sulkowski, Tarek Hassanein, Edward J. Gane, Lin Liu, Hongmei Mo, Brian Doehle, Bittoo Kanwar, Diana Brainard, G. Mani Subramanian, William T. Symonds, John G. McHutchison, Ronald G. Nahass, Michael Bennett, Ira M. Jacobson – 6 April 2015 – Retreatment of patients who have not achieved sustained virological response (SVR) after treatment with investigational direct‐acting antiviral agents (DAAs) has not been extensively studied.

Adeel A. Butt, Peng Yan, Hector Bonilla, Abdul‐Badi Abou‐Samra, Obaid S. Shaikh, Tracey G. Simon, Raymond T. Chung, Shari S. Rogal, for the ERCHIVES (Electronically Retrieved Cohort of HCV Infected Veterans) Study Team – 6 April 2015 – 3‐hydroxy‐3‐methylglutaryl coenzyme A reductase inhibitors (statins) have been variably noted to affect hepatitis C virus (HCV) treatment response, fibrosis progression, and hepatocellular carcinoma (HCC) incidence, with some having a more potent effect than others.

Elliot B. Tapper, Daniel Finkelstein, Murray A. Mittleman, Gail Piatkowski, Michelle Lai – 4 April 2015 – The risk of morbidity and mortality for hospitalized patients with cirrhosis is high and incompletely captured by conventional indices. We sought to evaluate the predictive role of frailty in an observational cohort study of inpatients with decompensated cirrhosis between 2010 and 2013. The primary outcome was 90‐day mortality. Secondary outcomes included discharge to a rehabilitation hospital, 30‐day readmission, and length of stay.

Isabel Graupera, Pere Ginès – 4 April 2015

Jean‐Charles Nault, Julien Calderaro, Jessica Zucman‐Rossi – 4 April 2015

Eunkyong Ko, Eun Sun Jung, Guhung Jung – 4 April 2015

Jean‐Charles Nault, Sandra Rebouissou, Jessica Zucman Rossi – 4 April 2015